Internal Medicine, Hematology & Oncology · Norfolk, VA
NPI
1467445999
Since 2005
Specialty
Internal Medicine, Hematology & Oncology
Code 207RH0003X
Group practices
1
Medicare group memberships
Hospitals
5
Hospital affiliations
5900 Lake Wright Dr
Norfolk, VA, 23502
Phone (757) 466-8683
Groups this clinician bills Medicare through
Medicare paid, 2024
$2.4M
137,065 services
Medicare patients, 2024
878
Average age 74
Drug cost, 2024
$3.0M
1,020 prescriptions
Company payments, 2025
$10K
From 15 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Michael A Danso was code J9271 (injection, pembrolizumab, 1 mg), 9,600 times for 18 patients. In total Michael A Danso billed 137,065 services in 201 codes, and Medicare paid $2.4M.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2014-09-22.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| J9271 Injection, pembrolizumab, 1 mg | Office | 9,600 | 18 | $44.46 | $427K |
| J1453 Injection, fosaprepitant, 1 mg | Office | 8,700 | 24 | $0.11 | $992 |
| J0881 Injection, darbepoetin alfa, 1 microgram (non-esrd use) | Office | 8,340 | 13 | $2.35 | $20K |
| J9299 Injection, nivolumab, 1 mg | Office | 7,480 | 12 | $23.05 | $172K |
| J0897 Injection, denosumab, 1 mg | Office | 6,720 | 56 | $20.27 | $136K |
| J9267 Injection, paclitaxel, 1 mg | Office | 6,594 | 16 | $0.08 | $526 |
| J0185 Injection, aprepitant, 1 mg | Office | 2,730 | 14 | $1.32 | $3,606 |
| 85025 Blood Count | Office | 2,061 | 549 | $7.55 | $16K |
| J1100 Injection, dexamethasone sodium phosphate, 1 mg | Office | 1,948 | 68 | $0.09 | $176 |
| 80053 Clinical Chemistry | Office | 1,751 | 529 | $10.27 | $18K |
| J2469 Injection, palonosetron hcl, 25 mcg | Office | 1,270 | 49 | $0.73 | $931 |
| J9395 Injection, fulvestrant, 25 mg | Office | 1,120 | 11 | $6.45 | $7,226 |
| J9394 Injection, fulvestrant (fresenius kabi) not therapeutically equivalent to j9395, 25 mg | Office | 980 | 13 | $24.42 | $24K |
| 36415 Venipuncture Blood Collection | Office | 959 | 388 | $8.59 | $8,237 |
| 86300 Immunoassay | Office | 795 | 327 | $20.18 | $16K |
By year: 2022 $3.2M for 196,696 services; 2023 $2.9M for 169,532 services; 2024 $2.4M for 137,065 services.
Lab tests billed to Medicare, 2024
| Test code | Tests | Patients | Paid per test | Medicare paid |
|---|---|---|---|---|
| 85025 Blood Count | 2,061 | 549 | $7.55 | $16K |
| 80053 Clinical Chemistry | 1,751 | 529 | $10.27 | $18K |
| 36415 Venipuncture Blood Collection | 959 | 388 | $8.59 | $8,237 |
| 86300 Immunoassay | 795 | 327 | $20.18 | $16K |
| 88185 Surgical Pathology Examination | 635 | 27 | $17.06 | $11K |
| 82784 Immunoassay | 246 | 62 | $8.91 | $2,191 |
| 82728 Clinical Chemistry | 236 | 144 | $13.16 | $3,105 |
| 83540 Clinical Chemistry | 235 | 144 | $6.24 | $1,466 |
| 83550 Clinical Chemistry | 235 | 144 | $8.43 | $1,981 |
| 82607 Clinical Chemistry | 192 | 141 | $14.57 | $2,797 |
Medicare prescription drug claims, 2024
In 2024, the drug Michael A Danso prescribed most often to Medicare patients was Letrozole, with 348 prescriptions and refills. In total Michael A Danso wrote 1,020 Medicare prescriptions that cost $3.0M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Letrozole Generic | 348 | 812 | 119 | $6,581 |
| Anastrozole Generic | 123 | 263 | 43 | $2,163 |
| Exemestane Generic | 87 | 202 | 31 | $15K |
| Verzenio Abemaciclib | 78 | 78 | 14 | $1.2M |
| Ibrance Palbociclib | 54 | 55 | Under 11 | $827K |
| Xarelto Rivaroxaban | 36 | 48 | Under 11 | $24K |
| Ondansetron Hcl Generic | 30 | 30 | 22 | $604 |
| Eliquis Apixaban | 28 | 31 | Under 11 | $17K |
| Dexamethasone Generic | 23 | 23 | 13 | $399 |
| Olanzapine Generic | 22 | 22 | 11 | $233 |
| Acyclovir Generic | 19 | 19 | Under 11 | $126 |
| Prednisone Generic | 14 | 14 | Under 11 | $17.11 |
| Inrebic Fedratinib Dihydrochloride | 12 | 12 | Under 11 | $297K |
Brand drugs: 263 claims; generic drugs: 757 claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Michael A Danso $10K ($9,090 in general payments such as food, travel and fees and $1,097 for research) from 15 companies. The largest payer was AstraZeneca Pharmaceuticals LP with $6,165.
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP AZN | 4 | $6,165 |
| AstraZeneca UK Limited AZN | 2 | $1,110 |
| Novartis Pharmaceuticals Corporation NVS | 1 | $1,097 |
| Genentech USA, Inc. ROG.SW | 1 | $803 |
| Merck Sharp & Dohme LLC MRK | 4 | $451 |
| Gilead Sciences, Inc. GILD | 2 | $232 |
| Array Biopharma Inc PFE | 1 | $150 |
| Jazz Pharmaceuticals Inc. JAZZ | 1 | $100 |
| Daiichi Sankyo Inc. 4568.T | 1 | $79.03 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.